Labcorp Holdings Reaches New 52-Week High of $315.65

Labcorp Holdings, Inc. has reached a significant milestone by hitting a new 52-week high of USD 315.65 on July 28, 2026. This achievement underscores the company's robust performance within the Pharmaceuticals & Biotechnology sector, where it operates as a mid-cap entity with a market capitalization of USD 21.77 billion. Over the past year, Labcorp has demonstrated a performance increase of 16.26%, outperforming the S&P 500. The company's price-to-earnings (P/E) ratio stands at 22.00, reflecting its valuation in the market. Additionally, Labcorp's price-to-book ratio is recorded at 2.53, indicating the relationship between its market value and book value. Despite a dividend yield of 0.00%, the company maintains a debt-to-equity ratio of 0.61, suggesting a balanced approach to leveraging. However, it is noteworthy that the return on equity figure appears unusually high, indicating potential anomalies in financial reporting. Overall, Labcorp's recent price achievement highlights its competitive position in the market and reflects the underlying trends within the industry.